About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Irf1tm1Mak
targeted mutation 1, Tak Mak
MGI:1857205
Summary 9 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Irf1tm1Mak/Irf1tm1Mak B6.129S2-Irf1tm1Mak/J MGI:3769118
hm2
Irf1tm1Mak/Irf1tm1Mak either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2) MGI:2180209
hm3
Irf1tm1Mak/Irf1tm1Mak involves: 129S2/SvPas MGI:3769119
hm4
Irf1tm1Mak/Irf1tm1Mak involves: 129S2/SvPas * C57BL/6J MGI:3769123
ht5
Irf1tm1Mak/Irf1+ either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2) MGI:3769111
cx6
Irf1tm1Mak/Irf1tm1Mak
Tg(HRAS)2Jic/?
involves: 129S2/SvPas * BALB/c * C57BL/6 MGI:4819237
cx7
Irf1tm1Mak/Irf1tm1Mak
Trp53tm1Sia/Trp53tm1Sia
involves: 129S2/SvPas * C57BL/6 * CBA MGI:4819238
cx8
Faslpr/Faslpr
Irf1tm1Mak/Irf1tm1Mak
MRL.Cg-Irf1tm1Mak Faslpr MGI:3769143
cx9
Faslpr/Faslpr
Irf1tm1Mak/Irf1+
MRL.Cg-Irf1tm1Mak Faslpr MGI:3769144


Genotype
MGI:3769118
hm1
Allelic
Composition
Irf1tm1Mak/Irf1tm1Mak
Genetic
Background
B6.129S2-Irf1tm1Mak/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls
• treatment with recombinant IL12 significantly improves survival of MNU treated mice

homeostasis/metabolism
• when subjected to warm ischemia/reperfusion (I/R), 60 minutes of warm hepatic ischemia followed by 6 hours of reperfusion significantly increase serum ALT levels in controls, but levels in treated mutants are ~60% lower than I/R-treated wild-type mice
• increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls
• treatment with recombinant IL12 significantly improves survival of MNU treated mice
• following a single dose of MNU most mice develop massive lymphoid neoplasias
• treatment with recombinant IL12 reduces the incidence of lymphomas in MNU treated mice

immune system
• impairment in the ability to produce IFNG in response to Con A stimulation
• IL12 treatment can rescue the impairment in IFNG production
• by lymphocytes following Con A stimulation
• IL12 treatment can rescue the impairment in IFNG production

neoplasm
• following a single dose of MNU most mice develop massive lymphoid neoplasias
• treatment with recombinant IL12 reduces the incidence of lymphomas in MNU treated mice
• following a single dose of MNU compared to similarly treated wild-type controls

hematopoietic system
• impairment in the ability to produce IFNG in response to Con A stimulation
• IL12 treatment can rescue the impairment in IFNG production




Genotype
MGI:2180209
hm2
Allelic
Composition
Irf1tm1Mak/Irf1tm1Mak
Genetic
Background
either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• CD8+/CD4+ T cell ratio is lower than wild-type or Irf2-deficient mice during course of LCMV infection
• numbers are normal or slightly increased in thymi
• CD4+CD8- T cells are often but not always increased in number in homozygotes
• 10-fold reduction in TCR alpha-beta CD4-CD8+ T cells is observed in peripheral blood, spleen, thymus, and lymph nodes

immune system
N
• humoral response to vesicular stomatitis virus challenge is normal; kinetics of immunoglobulin class switching and antibody levels are comparable to wild-type mice
• CD8+/CD4+ T cell ratio is lower than wild-type or Irf2-deficient mice during course of LCMV infection
• numbers are normal or slightly increased in thymi
• CD4+CD8- T cells are often but not always increased in number in homozygotes
• 10-fold reduction in TCR alpha-beta CD4-CD8+ T cells is observed in peripheral blood, spleen, thymus, and lymph nodes
• significantly reduced cytotoxic responses against LCMV-infected target cells are observed




Genotype
MGI:3769119
hm3
Allelic
Composition
Irf1tm1Mak/Irf1tm1Mak
Genetic
Background
involves: 129S2/SvPas
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
N
• apoptosis following UV-induced damage is similar in mutant primary hepatocytes from 6-10 week males and wild-type cells
• 6-12 hours after UV irradiation, hepatocytes arrest in at G1/S, similar to wild-type cells
• cultured hepatocytes from 6-10 week males show a defect in DNA repair in an assay in which repair of a UV-damaged reporter plasmid by wild-type and null hepatocytes; recovery of reporter activity by Irf1-deficient hepatocytes is significantly lower than that of wild-type or Trp53-deficient cells

homeostasis/metabolism
• cultured hepatocytes from 6-10 week males show a defect in DNA repair in an assay in which repair of a UV-damaged reporter plasmid by wild-type and null hepatocytes; recovery of reporter activity by Irf1-deficient hepatocytes is significantly lower than that of wild-type or Trp53-deficient cells




Genotype
MGI:3769123
hm4
Allelic
Composition
Irf1tm1Mak/Irf1tm1Mak
Genetic
Background
involves: 129S2/SvPas * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• 28 days after induction of flow cessation in the common carotid artery, a significant increase of neointima formation was observed proximal of the ligation suture in mutants compared to control wild-type mice

homeostasis/metabolism
• 28 days after induction of flow cessation in the common carotid artery, a significant increase of neointima formation was observed proximal of the ligation suture in mutants compared to control wild-type mice




Genotype
MGI:3769111
ht5
Allelic
Composition
Irf1tm1Mak/Irf1+
Genetic
Background
either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• mice are viable and fertile, with no detectable abnormalities




Genotype
MGI:4819237
cx6
Allelic
Composition
Irf1tm1Mak/Irf1tm1Mak
Tg(HRAS)2Jic/?
Genetic
Background
involves: 129S2/SvPas * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
Tg(HRAS)2Jic mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 44% develop tumors as compared to 7% of controls
• angiosarcomas observed most frequently




Genotype
MGI:4819238
cx7
Allelic
Composition
Irf1tm1Mak/Irf1tm1Mak
Trp53tm1Sia/Trp53tm1Sia
Genetic
Background
involves: 129S2/SvPas * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
Trp53tm1Sia mutation (11 available); any Trp53 mutation (150 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• earlier tumor induced death

neoplasm
• 96% develop tumors by 299 days of age compared to 56% of mice only homozygous for Trp53tm1Sia
• greater frequency of multiple tumors
• immature teratomas




Genotype
MGI:3769143
cx8
Allelic
Composition
Faslpr/Faslpr
Irf1tm1Mak/Irf1tm1Mak
Genetic
Background
MRL.Cg-Irf1tm1Mak Faslpr
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Faslpr mutation (30 available); any Fas mutation (48 available)
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 50% of mice die by 45 weeks; survival is increased relative to MRL-Faslpr mice

immune system
N
• TNF alpha production is not significantly different from Faslpr, Irf1-sufficient mice
• at 12 weeks, splenic CD4+CD25+ T cells are increased in percentage compared to wild-type MRL-Faslpr mice; percentage increases from 27.1% at 8 weeks to 40.3% at 26 weeks in wild-type mice, double mutants have 60.6% at 26 weeks
• 26 week old mice have a percentage of CD4+CD25+CD62L+ T cells (32.2%) compared to wild-type MRL-Faslpr mice (13.1%)
• mesangial cells from 8- and 26-week old mice show significantly less Il12 production than Faslpr, Irf1-sufficient cells upon stimulation with LPS and interferon gamma
• levels of anti-dsDNA IgG2a are significantly decreased relative to Faslpr, Irf1-sufficient mice
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes

hematopoietic system
• at 12 weeks, splenic CD4+CD25+ T cells are increased in percentage compared to wild-type MRL-Faslpr mice; percentage increases from 27.1% at 8 weeks to 40.3% at 26 weeks in wild-type mice, double mutants have 60.6% at 26 weeks
• 26 week old mice have a percentage of CD4+CD25+CD62L+ T cells (32.2%) compared to wild-type MRL-Faslpr mice (13.1%)

renal/urinary system
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes

homeostasis/metabolism
N
• only 1 mouse had abnormal urine protein levels (above 200 mg/dl) at 24 weeks of age

cellular
• in response to LPS + IFN gamma stimulation, mesangial cells show significantly lower activation than cells from MRL-Faslpr mice

integument
N
• mice do not show characteristic signs of skin disease; at 26 weeks of age, 7/10 mice show no skin involvement, while 3 show minimal skin irritation, compared to 8/10 Faslpr, Irf1 sufficient mice displaying moderate to severe skin involvement




Genotype
MGI:3769144
cx9
Allelic
Composition
Faslpr/Faslpr
Irf1tm1Mak/Irf1+
Genetic
Background
MRL.Cg-Irf1tm1Mak Faslpr
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Faslpr mutation (30 available); any Fas mutation (48 available)
Irf1tm1Mak mutation (1 available); any Irf1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 50% of mice die by 52 weeks; survival is increased relative to MRL-Faslpr mice

renal/urinary system
• not significantly different from Faslpr, Irf1-null mice or Faslpr, Irf1-sufficient mice
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes

hematopoietic system
• mice display similar T cell population profiles to Faslpr, Irf1-null mice

immune system
N
• TNF alpha production is not significantly different Faslpr, Irf1-sufficient mice or Faslpr, Irf1-null mice
• mice display similar T cell population profiles to Faslpr, Irf1-null mice
• at 26 weeks of age, levels are significantly higher relative to Faslpr, Irf1-null mice
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes

homeostasis/metabolism
• not significantly different from Faslpr, Irf1-null mice or Faslpr, Irf1-sufficient mice

integument
• mice display varying severity of skin irritation ranging from little or none to mild or moderate to severe





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
08/13/2019
MGI 6.14
The Jackson Laboratory